Dr. Christoph Correll, Professor of Psychiatry at the Zucker School of Medicine discusses common misconceptions about schizophrenia and the challenges that people experience when managing this condition, including adherence to medication and the risk of relapse. Dr. Correll also discusses a recently-approved treatment for adults with schizophrenia called UZEDY™ (risperidone) extended-release injectable suspension, and new data that build on our existing knowledge about this treatment option.

Christoph Correll, MD, is professor of psychiatry at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell and a medical director of the Recognition and Prevention (RAP) program at Zucker Hillside Hospital. He also currently serves as professor and chair of the Department of Child and Adolescent Psychiatry at Charité University Medicine in Berlin, Germany. He completed his medical studies at the Free University of Berlin in Germany and Dundee University Medical School in Scotland. He is board certified in general psychiatry and child and adolescent psychiatry, having completed both residencies at Zucker Hillside Hospital in New York City. Since 1997, he has been conducting research in New York, and in 2017, began working in Germany again.

Professor Correll has authored and co-authored more than 700 journal articles. He has served on several expert consensus panels on the use of antipsychotics across a range of psychiatric disorders, is a reviewer for more than 70 peer-reviewed journals and an editorial board member of 12 scientific journals. Professor Correll is the Principal Investigator or Steering Committee member of several large, federally funded grants. He has received more than 30 national and international research awards and fellowships for his work. Since 2014, the year of inception of this metric, he has been listed each year by Thomson Reuters/Clarivate/Web of Science as one of “The most influential scientific minds” and “Top 1% cited scientists in the area of psychiatry.”

Professor Correll’s research and clinical work focus on the identification, characterization and psychopharmacological management of adults and youth with severe psychiatric disorders. His areas of expertise include schizophrenia, bipolar disorder, major depression and other psychotic, mood and autism/disruptive behavior spectrum disorders, ranging from the prodrome to first episode, multi-episode and refractory illness patients. His work focuses further on psychopharmacology, epidemiology, clinical trials, comparative effectiveness, meta-analyses, the risk–benefit evaluation of psychotropic medications, and the interface between physical health and mental health.

Liked it? Take a second to support healthprofessionalradio on Patreon!